- Home
- RITR vs INBX Comparison
RITR vs INBX Comparison
Compare RITR & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RITR
- INBX
- Stock Information
- Founded
- RITR 2015
- INBX 2010
- Country
- RITR Hong Kong
- INBX United States
- Employees
- RITR N/A
- INBX N/A
- Industry
- RITR
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- RITR
- INBX Health Care
- Exchange
- RITR NYSE
- INBX Nasdaq
- Market Cap
- RITR 233.5M
- INBX 218.9M
- IPO Year
- RITR 2024
- INBX 2020
- Fundamental
- Price
- RITR $3.89
- INBX $14.19
- Analyst Decision
- RITR
- INBX Hold
- Analyst Count
- RITR 0
- INBX 1
- Target Price
- RITR N/A
- INBX N/A
- AVG Volume (30 Days)
- RITR 80.9K
- INBX 80.6K
- Earning Date
- RITR 02-15-2025
- INBX 11-14-2024
- Dividend Yield
- RITR N/A
- INBX N/A
- EPS Growth
- RITR N/A
- INBX N/A
- EPS
- RITR 0.04
- INBX 119.38
- Revenue
- RITR $32,198,033.00
- INBX $1,568,000.00
- Revenue This Year
- RITR N/A
- INBX N/A
- Revenue Next Year
- RITR N/A
- INBX N/A
- P/E Ratio
- RITR $84.60
- INBX $0.11
- Revenue Growth
- RITR 74.80
- INBX 19.24
- 52 Week Low
- RITR $2.35
- INBX $10.80
- 52 Week High
- RITR $8.75
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- RITR N/A
- INBX 47.10
- Support Level
- RITR N/A
- INBX $12.51
- Resistance Level
- RITR N/A
- INBX $14.86
- Average True Range (ATR)
- RITR 0.00
- INBX 1.05
- MACD
- RITR 0.00
- INBX -0.14
- Stochastic Oscillator
- RITR 0.00
- INBX 38.89
About RITR REITAR LOGTECH HLDGS LTD
Reitar Logtech Holdings Ltd provide one-stop solutions for logistics property operations in property development and redevelopment projects. It consists of two segments: construction management and engineering design services; and asset management and professional consultancy services in Hong Kong. Key revenue is generated from construction management and engineering design services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.